Checkpoint Inhibitor denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Your Checkpoint Inhibitor — "Not FDA-Approved"

Checkpoint inhibitors (drugs that block PD-1, PD-L1, or CTLA-4 pathways) are FDA-approved for a growing but specific list of cancer types, stages, and biomarker profiles. Cigna's "not FDA-approved" denial almost always means one of three things: the requested drug lacks FDA approval for your exact tumor type or line of therapy; you are being treated off-label for a use not yet reflected in Cigna's coverage policy; or there was a coding mismatch between the ICD-10 diagnosis submitted and the approved indication.

This denial is frequently wrong or, at minimum, appealable — because many off-label oncology uses are supported by compendia (NCCN, Micromedex, DrugDex) that federal law and most state laws require insurers to cover on equal footing with labeled uses.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial notice. Cigna must decide urgent oncology appeals within 72 hours (expedited) or 30 days (standard).
• External review (ACA §2719): After exhausting or partially exhausting internal appeal, you may request independent external review. The ~4-month window from denial to external review deadline is strictly enforced — do not wait.
• ERISA §503 (if employer-sponsored): Requires a full-and-fair review with access to the clinical criteria used; you can request the full file.
• Expedited option: For active cancer treatment, request expedited review at every level simultaneously.

## Documentation to Gather

1. Diagnosis confirmation: Pathology report, staging workup, biomarker/genomic testing results (PD-L1 expression, MSI/TMB, tumor mutation burden, or other relevant markers). 2. Prescriber's medical-necessity letter: Should map the requested agent to the FDA-approved label OR to a recognized compendia listing (e.g., the applicable NCCN guideline category), explain why this agent is appropriate for this patient's histology and line of therapy, and state that alternatives are not suitable. 3. Compendia citation: Ask your oncologist to identify the specific NCCN compendium entry or equivalent that supports the use; this is the primary legal lever for off-label coverage. 4. Prior treatment history: Document each prior line of therapy with dates and outcomes to establish line-of-therapy sequencing. 5. Denial letter and criteria: Obtain Cigna's full coverage policy for the requested drug; you are entitled to this under ERISA or ACA.

## Criteria-Mapping Structure

Build a table: copy each requirement from (a) the FDA-approved prescribing label for the specific checkpoint inhibitor and (b) Cigna's published medical policy for this drug. For each requirement, supply the exact chart fact that satisfies it — biomarker result with date, histology confirmation, ECOG performance status, line of therapy. A point-by-point match is far more persuasive than a narrative letter alone.

If the use is off-label, the central argument shifts: cite the compendia listing and state that applicable law requires coverage of compendia-supported oncology uses. Include the oncologist's attestation that the use is consistent with current evidence-based practice.